celecoxib has been researched along with Cancer of Prostate in 90 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of celecoxib appears to result in decreased urinary retention following prostate brachytherapy." | 9.10 | Celecoxib to decrease urinary retention associated with prostate brachytherapy. ( Feigenberg, SJ; Morris, CG; Wolk, KL; Yang, CH; Zlotecki, RA, 2003) |
| "Finally, GTN and Celecoxib controlled inflammation in the prostate, and sensitized the senescent microenvironment to anti-inflammatory stimuli." | 7.85 | Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders. ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Vendramini-Costa, DB, 2017) |
| " This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model." | 7.72 | Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004) |
| "The use of celecoxib appears to result in decreased urinary retention following prostate brachytherapy." | 5.10 | Celecoxib to decrease urinary retention associated with prostate brachytherapy. ( Feigenberg, SJ; Morris, CG; Wolk, KL; Yang, CH; Zlotecki, RA, 2003) |
| " The objective was to evaluate the morphological, hormonal, and inflammatory responses in the prostate anterior lobe in transgenic adenocarcinoma of the mouse prostate (TRAMP), following Celecoxib and Goniothalamin (GTN) treatments." | 3.88 | Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice. ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Silva, RS; Vendramini-Costa, DB, 2018) |
| "Finally, GTN and Celecoxib controlled inflammation in the prostate, and sensitized the senescent microenvironment to anti-inflammatory stimuli." | 3.85 | Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders. ( Cagnon, VHA; Kido, LA; Montico, F; Pilli, RA; Vendramini-Costa, DB, 2017) |
| "The aim of this study was to characterize the structural and molecular biology as well as evaluate the immediate and late responses of prostatic cancer in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model after treatment with goniothalamin (GTN) and celecoxib." | 3.83 | Anti-inflammatory therapies in TRAMP mice: delay in PCa progression. ( Cagnon, VH; Carvalho, JE; Costa, DB; Kido, LA; Macedo, AB; Minatel, E; Montico, F; Pilli, RA; Sauce, R, 2016) |
| "Dietary supplement of celecoxib at doses of 400 ppm, 600 ppm, and 1,000 ppm are most effective against mPIN (mouse prostatic intraepithelial neoplasia) and adenocarcinoma of the prostate." | 3.73 | Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition. ( Narayanan, BA; Narayanan, NK; Pttman, B; Reddy, BS, 2006) |
| "We found for the first time that (a) both celecoxib and exisulind as dietary supplements induce strong inhibitory effects against prostate cancer at doses of 800 and 500 ppm, respectively, after 16 weeks; (b) the histologic analysis of the dorsolateral prostate after 2 weeks of treatment indicated a reduction of PIN lesions from 75% to 19% with celecoxib and to 16% with exisulind; (c) more importantly, those few PINs and adenocarcinomas in the groups treated with celecoxib or exisulind showed more apoptotic cells, lower levels of proliferating cell nuclear antigen, and a lower number of mitotic cells." | 3.72 | Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. ( Narayanan, BA; Narayanan, NK; Pittman, B; Reddy, BS, 2004) |
| " This prompted us to investigate the chemopreventive potential of celecoxib, a selective COX-2 inhibitor, against prostate carcinogenesis in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model." | 3.72 | Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. ( Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M, 2004) |
| "Patients with localised prostate cancer were randomised to receive either celecoxib 400 mg twice daily or placebo for 4 weeks before RP." | 2.84 | Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo. ( Beer, TM; Eilers, KM; Flamiatos, JF; Garzotto, M; Graff, JN; Sekhon, HS; Tian, W, 2017) |
| "There were 303 control arm deaths (83% prostate cancer), and median survival was 66 months." | 2.84 | Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. ( Attard, G; Barber, J; Cassoly, E; Clarke, NW; Cross, W; Dearnaley, DP; Gilson, C; Ibrahim, A; James, ND; Jones, RJ; Logue, J; Lydon, A; Mason, MD; Matheson, D; Millman, R; Nikapota, AD; O'Sullivan, JM; Parker, CC; Parmar, MKB; Porfiri, E; Protheroe, A; Rentsch, CA; Ritchie, AWS; Russell, JM; Schiavone, F; Spears, MR; Srihari, NN; Sydes, MR; Thalmann, GN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C, 2017) |
| "44 men with advanced hormoneresistant prostate cancer participated in oncologic Phase II trials." | 2.77 | Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma. ( Benson, P; Chang, V; Kasimis, B; Sims, D; Srinivas, S; Yudd, M, 2012) |
| "Patients with cT1-2 prostate cancer (n=45) were randomized to celecoxib 400mg b." | 2.74 | A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. ( Coley, HM; Eden, CG; Fox, SB; Henderson, A; Laing, RW; Langley, SE; Lovell, DP; Macanas-Pirard, P; Miller, PD; Sooriakumaran, P, 2009) |
| " VE-C gene expression and VEGF levels represent potentially useful pharmacodynamic markers for the clinical response." | 2.74 | Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. ( Allegrini, G; Antonuzzo, A; Bocci, G; Bursi, S; D'Arcangelo, M; Danesi, R; Del Tacca, M; Di Marsico, R; Falcone, A; Fioravanti, A; Fontana, A; Fontana, E; Galli, C; Galli, L; Landi, L; Orlandi, P, 2009) |
| "Patients with localized prostate cancer and Gleason sum > or = 7, prostate-specific antigen (PSA) > or = 15 ng/mL, clinical stage T2b or greater, or any combination with greater than 45% risk of capsular penetration were randomly assigned to celecoxib 400 mg by mouth twice daily or placebo for 4 to 6 weeks before prostatectomy." | 2.74 | Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. ( Antonarakis, ES; Baker, SD; Carducci, MA; Dannenberg, AJ; De Marzo, AM; DeWeese, TL; Fedor, H; Gurganus, RT; Heath, EI; Nelson, WG; Parnes, HL; Partin, AW; Piantadosi, S; Walczak, JR; Zahurak, ML, 2009) |
| "Celecoxib was given 400 mg twice daily with onset of the radiation treatment." | 2.72 | Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. ( Bamberg, M; Becker, G; Belka, C; Budach, W; Ganswindt, U; Jendrossek, V, 2006) |
| "Paclitaxel has antiangiogenic properties, but the mechanisms for the enhanced sensitivity of endothelial cells (ECs) to this drug are not established." | 2.71 | Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. ( Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG, 2005) |
| "The fifth case was a breast cancer patient with distant metastases in CR, while receiving beta-interferon and interleukin-2 in addition to conventional hormone therapy." | 1.51 | Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. ( Carpi, A; Ferrari, P; Morganti, R; Nicolini, A, 2019) |
| "Globally, prostate cancer remains a challenging health burden for men as it is the second leading cause of cancer death in men and about one in nine will be diagnosed with prostate cancer in his lifetime." | 1.51 | Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation. ( Chen, Y; Guo, F; Li, Y; Tian, J; Yu, B, 2019) |
| "We established two docetaxel‑resistant prostate cancer cell lines, PC3/DR and DU145/DR, by culturing PC3 and DU145 cells in docetaxel in a dose‑escalating manner." | 1.48 | Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. ( Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG, 2018) |
| "Inflammation plays a central role in prostate cancer (PCa) development through significant crosstalk between the COX-2-ErbB family receptor network and androgen receptor (AR)-EGFR signaling pathways." | 1.46 | The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. ( Barboro, P; Benelli, R; Brizzolara, A; Ferrari, N; Poggi, A; Tosetti, F; Venè, R, 2017) |
| "Chemokine expression in prostate cancer lesion was analyzed by TaqMan-based quantitative PCR, confocal fluorescence microscopy and ELISA." | 1.43 | Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. ( Chatta, GS; Corman, JM; Dahl, K; Kalinski, P; Muthuswamy, R, 2016) |
| "We recently demonstrated that both murine and human carcinomas grow significantly slower in mice on low carbohydrate (CHO), high protein diets than on isocaloric Western diets and that a further reduction in tumor growth rates occur when the low CHO diets are combined with the cyclooxygenase-2 inhibitor, celecoxib." | 1.40 | A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. ( Adomat, HH; Bennewith, KL; Dang, NH; Guns, ES; Hamilton, MJ; Ho, VW; Hsu, BE; Krystal, G; Samudio, I; Weljie, A, 2014) |
| "Celecoxib is a selective COX-2 inhibitor and reported to prevent the progression of prostate cancer." | 1.40 | EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer. ( Inokuchi, J; Kashiwagi, E; Naito, S; Shiota, M; Uchiumi, T; Yokomizo, A, 2014) |
| "Murine prostate cancer cells (RM9) were intravenously injected and lung metastasis was estimated by counting colonies in the lungs." | 1.40 | Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells. ( Akira, S; Amano, H; Ikeda, M; Iwamura, M; Kitasato, H; Majima, M; Satoh, T; Tabata, K; Takahashi, R, 2014) |
| "Celecoxib reduces the growth of prostate cancer cell lines in part by decreasing proliferation, which suggests that the inhibition of growth of LNCaP cells by celecoxib is independent of normal levels of native p53." | 1.39 | Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. ( Abdulkadir, SA; Chatla, C; Grizzle, WE; Katkoori, VR; Manne, K; Manne, U; Rodríguez-Burford, C; Shanmugam, C; Sthanam, M; Vital-Reyes, VS, 2013) |
| "Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities." | 1.38 | Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib. ( Marschner, N; Zaiss, M, 2012) |
| "Celecoxib has been shown to have an antitumor effect in previous studies, but the mechanisms are unclear." | 1.38 | Effect of celecoxib on Ca(2+) handling and viability in human prostate cancer cells (PC3). ( Chang, HT; Chen, IS; Cheng, JS; Chou, CT; Hsu, SS; Jan, CR; Kuo, CC; Liao, WC; Lin, KL; Liu, SI; Lu, YC; Tsai, JY; Wang, JL, 2012) |
| "Leukotriene B4 (LTB4) has been implicated in prostate and colon carcinogenesis, but little is known about the potential role of LTB4 in celecoxib-mediated anticancer effect." | 1.36 | Role of leukotriene B4 in celecoxib-mediated anticancer effect. ( Gao, P; Guan, L; Zheng, J, 2010) |
| "We conclude for the first time that prostate cancer induced by MNU plus testosterone partly involves mediators of inflammation which could trigger the process of carcinogenesis and cause loss of apoptosis." | 1.35 | Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. ( Bosland, MC; Horton, L; Narayanan, BA; Narayanan, NK; Nargi, D; Reddy, BS, 2009) |
| "We have explored the role of COX-2 in prostate cancer in terms of attenuation of apoptosis and sensitivity to pharmacological agents, including COX-2 inhibitors." | 1.35 | The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. ( Coley, HM; Kass, GE; Macanas-Pirard, P; Mehar, A; Mizokami, A; Takahashi, Y, 2008) |
| "Treatment with celecoxib alone or in combination with IR led to a dose-dependent increase in COX-2 protein expression." | 1.34 | Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. ( Dittmann, K; Kehlbach, R; Krebiehl, G; Ohneseit, PA; Rodemann, HP, 2007) |
| "Human prostate cancer cells LNCaP, PC-3, and CWR22Rnu1 were treated with EGCG and NS398 alone and in combination, and their effect on growth and apoptosis was evaluated." | 1.34 | Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. ( Adhami, VM; Afaq, F; Malik, A; Mukhtar, H; Pasha, FS; Saleem, M; Sarfaraz, S; Siddiqui, IA; Syed, DN; Zaman, N, 2007) |
| "Human prostate cancer PC-3 cells in culture were treated with atorvastatin and celecoxib alone or in combination." | 1.34 | Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. ( Avila, GE; Conney, AH; Cui, XX; Huang, MT; Kong, AN; Lin, Y; Liu, Y; Patel, J; Paulino, R; Rabson, AB; Reddy, BS; Shih, WJ; Zheng, X, 2007) |
| "The rats that received celecoxib in combination with exisulind at low doses showed a significant decrease in prostatic intraepithelial neoplasia and adenocarcinomas as well as an enhanced rate of apoptosis." | 1.34 | Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. ( Bosland, MC; Horton, L; Narayanan, BA; Narayanan, NK; Nargi, D; Randolph, C; Reddy, BS, 2007) |
| " These observations suggest a potential clinical use of combined dosing of COX-2 inhibitors and cytotoxic drugs at lower, nontoxic dose than currently used to treat advanced prostate cancer." | 1.33 | Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. ( Carey, RI; Dandekar, DS; Lokeshwar, BL; Lopez, M, 2005) |
| "A 48-h incubation of prostate cancer cells with 5 microM each of DHA or celecoxib induced cell growth inhibition and apoptosis, and altered the expression of the above molecular parameters." | 1.33 | A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. ( Narayanan, BA; Narayanan, NK; Reddy, BS, 2005) |
| "Treatment with celecoxib also led to dose-dependent inhibition of PC3 xenograft growth without causing a reduction in intratumor prostaglandin E(2)." | 1.33 | Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. ( Chang, M; Cordon-Cardo, C; Dannenberg, AJ; Du, B; Newman, RA; Patel, MI; Subbaramaiah, K; Thaler, HT; Yang, P, 2005) |
| " There is increasing interest in using COX-2 inhibitors in combination with other chemopreventive agents to overcome the issue of toxicity." | 1.33 | Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. ( Bosland, M; Condon, MS; Narayanan, BA; Narayanan, NK; Nargi, D, 2006) |
| "Celecoxib, however, is a weak PDK-1 inhibitor (IC(50), 48 microM), requiring at least 30 microM to exhibit discernable effects on the growth of tumor cells in vitro." | 1.32 | From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. ( Chen, CS; Fowble, J; Huang, JW; Kulp, SK; Shaw, YJ; Shiau, CW; Tseng, PH; Yang, YT; Zhu, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 45 (50.00) | 29.6817 |
| 2010's | 43 (47.78) | 24.3611 |
| 2020's | 2 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Pommery, N | 2 |
| Taverne, T | 1 |
| Telliez, A | 1 |
| Goossens, L | 1 |
| Charlier, C | 1 |
| Pommery, J | 2 |
| Goossens, JF | 1 |
| Houssin, R | 1 |
| Durant, F | 1 |
| Hénichart, JP | 2 |
| Bridoux, A | 1 |
| Millet, R | 1 |
| Liu, GZ | 1 |
| Xu, HW | 1 |
| Wang, P | 1 |
| Lin, ZT | 1 |
| Duan, YC | 1 |
| Zheng, JX | 1 |
| Liu, HM | 1 |
| Montico, F | 5 |
| Lamas, CA | 1 |
| Rossetto, IMU | 1 |
| Baseggio, AM | 1 |
| Cagnon, VHA | 4 |
| Nicolini, A | 1 |
| Ferrari, P | 1 |
| Morganti, R | 1 |
| Carpi, A | 1 |
| Griebling, TL | 1 |
| Ko, CJ | 1 |
| Lan, SW | 1 |
| Lu, YC | 2 |
| Cheng, TS | 1 |
| Lai, PF | 1 |
| Tsai, CH | 1 |
| Hsu, TW | 1 |
| Lin, HY | 1 |
| Shyu, HY | 1 |
| Wu, SR | 1 |
| Lin, HH | 1 |
| Hsiao, PW | 1 |
| Chen, CH | 1 |
| Huang, HP | 1 |
| Lee, MS | 1 |
| Brizzolara, A | 1 |
| Benelli, R | 1 |
| Venè, R | 1 |
| Barboro, P | 1 |
| Poggi, A | 1 |
| Tosetti, F | 1 |
| Ferrari, N | 1 |
| Silva, RS | 2 |
| Kido, LA | 4 |
| Vendramini-Costa, DB | 2 |
| Pilli, RA | 3 |
| Lin, JZ | 1 |
| Hameed, I | 1 |
| Xu, Z | 1 |
| Yu, Y | 1 |
| Ren, ZY | 1 |
| Zhu, JG | 1 |
| Mateus, PAM | 1 |
| Tian, J | 1 |
| Guo, F | 1 |
| Chen, Y | 1 |
| Li, Y | 2 |
| Yu, B | 1 |
| Zheng, Y | 1 |
| Comaills, V | 1 |
| Burr, R | 1 |
| Boulay, G | 1 |
| Miyamoto, DT | 1 |
| Wittner, BS | 1 |
| Emmons, E | 1 |
| Sil, S | 1 |
| Koulopoulos, MW | 1 |
| Broderick, KT | 1 |
| Tai, E | 1 |
| Rengarajan, S | 1 |
| Kulkarni, AS | 1 |
| Shioda, T | 1 |
| Wu, CL | 1 |
| Ramaswamy, S | 1 |
| Ting, DT | 1 |
| Toner, M | 1 |
| Rivera, MN | 1 |
| Maheswaran, S | 1 |
| Haber, DA | 1 |
| Landre, T | 1 |
| Guetz, GD | 1 |
| Chouahnia, K | 1 |
| Fossey-Diaz, V | 1 |
| Taleb, C | 1 |
| Culine, S | 1 |
| Orlandi, P | 3 |
| Fontana, A | 3 |
| Fioravanti, A | 3 |
| Di Desidero, T | 1 |
| Galli, L | 3 |
| Derosa, L | 2 |
| Canu, B | 1 |
| Marconcini, R | 1 |
| Biasco, E | 1 |
| Solini, A | 1 |
| Francia, G | 1 |
| Danesi, R | 3 |
| Falcone, A | 3 |
| Bocci, G | 3 |
| Garcia, M | 1 |
| Velez, R | 1 |
| Romagosa, C | 1 |
| Majem, B | 1 |
| Pedrola, N | 1 |
| Olivan, M | 1 |
| Rigau, M | 1 |
| Guiu, M | 1 |
| Gomis, RR | 1 |
| Morote, J | 1 |
| Reventós, J | 1 |
| Doll, A | 1 |
| Takahashi, R | 1 |
| Amano, H | 1 |
| Satoh, T | 1 |
| Tabata, K | 1 |
| Ikeda, M | 1 |
| Kitasato, H | 1 |
| Akira, S | 1 |
| Iwamura, M | 1 |
| Majima, M | 1 |
| Wang, H | 2 |
| Cui, XX | 4 |
| Goodin, S | 2 |
| Ding, N | 1 |
| Van Doren, J | 2 |
| Du, Z | 1 |
| Huang, MT | 3 |
| Liu, Y | 5 |
| Cheng, X | 1 |
| Dipaola, RS | 2 |
| Conney, AH | 4 |
| Zheng, X | 5 |
| Kashiwagi, E | 1 |
| Shiota, M | 1 |
| Yokomizo, A | 1 |
| Inokuchi, J | 1 |
| Uchiumi, T | 1 |
| Naito, S | 1 |
| Huang, H | 2 |
| Chen, S | 1 |
| He, Y | 1 |
| Li, D | 1 |
| Ho, VW | 1 |
| Hamilton, MJ | 1 |
| Dang, NH | 1 |
| Hsu, BE | 1 |
| Adomat, HH | 1 |
| Guns, ES | 1 |
| Weljie, A | 1 |
| Samudio, I | 1 |
| Bennewith, KL | 1 |
| Krystal, G | 1 |
| Yerokun, T | 1 |
| Winfield, LL | 1 |
| Ren, J | 1 |
| Zou, Q | 1 |
| Sauce, R | 1 |
| Macedo, AB | 1 |
| Minatel, E | 1 |
| Costa, DB | 1 |
| Carvalho, JE | 1 |
| Cagnon, VH | 1 |
| Muthuswamy, R | 1 |
| Corman, JM | 1 |
| Dahl, K | 1 |
| Chatta, GS | 1 |
| Kalinski, P | 1 |
| Flamiatos, JF | 1 |
| Beer, TM | 1 |
| Graff, JN | 1 |
| Eilers, KM | 1 |
| Tian, W | 1 |
| Sekhon, HS | 1 |
| Garzotto, M | 1 |
| Saad, F | 1 |
| Mason, MD | 4 |
| Clarke, NW | 4 |
| James, ND | 4 |
| Dearnaley, DP | 4 |
| Spears, MR | 1 |
| Ritchie, AWS | 1 |
| Attard, G | 1 |
| Cross, W | 1 |
| Jones, RJ | 1 |
| Parker, CC | 1 |
| Russell, JM | 2 |
| Thalmann, GN | 2 |
| Schiavone, F | 1 |
| Cassoly, E | 1 |
| Matheson, D | 1 |
| Millman, R | 1 |
| Rentsch, CA | 1 |
| Barber, J | 1 |
| Gilson, C | 1 |
| Ibrahim, A | 1 |
| Logue, J | 1 |
| Lydon, A | 1 |
| Nikapota, AD | 1 |
| O'Sullivan, JM | 2 |
| Porfiri, E | 1 |
| Protheroe, A | 2 |
| Srihari, NN | 1 |
| Tsang, D | 1 |
| Wagstaff, J | 1 |
| Wallace, J | 1 |
| Walmsley, C | 1 |
| Parmar, MKB | 1 |
| Sydes, MR | 4 |
| Xu, S | 1 |
| Zhou, WQ | 1 |
| Zhang, ZY | 1 |
| Ge, JP | 1 |
| Gao, JP | 1 |
| Anderson, J | 3 |
| Popert, RJ | 2 |
| Sanders, K | 3 |
| Morgan, RC | 2 |
| Stansfeld, J | 2 |
| Dwyer, J | 3 |
| Masters, J | 2 |
| Parmar, MK | 3 |
| Narayanan, NK | 7 |
| Nargi, D | 3 |
| Horton, L | 2 |
| Reddy, BS | 7 |
| Bosland, MC | 3 |
| Narayanan, BA | 7 |
| Handrick, R | 1 |
| Ganswindt, U | 2 |
| Faltin, H | 1 |
| Goecke, B | 1 |
| Daniel, PT | 1 |
| Budach, W | 2 |
| Belka, C | 2 |
| Jendrossek, V | 2 |
| Sooriakumaran, P | 1 |
| Coley, HM | 2 |
| Fox, SB | 1 |
| Macanas-Pirard, P | 2 |
| Lovell, DP | 1 |
| Henderson, A | 1 |
| Eden, CG | 1 |
| Miller, PD | 1 |
| Langley, SE | 1 |
| Laing, RW | 1 |
| Galli, C | 1 |
| Landi, L | 2 |
| Bursi, S | 2 |
| Allegrini, G | 1 |
| Fontana, E | 1 |
| Di Marsico, R | 1 |
| Antonuzzo, A | 1 |
| D'Arcangelo, M | 2 |
| Del Tacca, M | 1 |
| Efstathiou, E | 1 |
| Kim, J | 1 |
| Logothetis, CJ | 1 |
| Antonarakis, ES | 1 |
| Heath, EI | 2 |
| Walczak, JR | 1 |
| Nelson, WG | 2 |
| Fedor, H | 1 |
| De Marzo, AM | 2 |
| Zahurak, ML | 1 |
| Piantadosi, S | 1 |
| Dannenberg, AJ | 2 |
| Gurganus, RT | 1 |
| Baker, SD | 1 |
| Parnes, HL | 1 |
| DeWeese, TL | 2 |
| Partin, AW | 2 |
| Carducci, MA | 2 |
| Gao, Z | 1 |
| Zhao, Y | 1 |
| Lin, Y | 2 |
| Shih, WJ | 2 |
| Rabson, A | 1 |
| Reddy, B | 1 |
| Yang, CS | 1 |
| Mathew, P | 1 |
| Barletta, MT | 1 |
| Minuti, G | 1 |
| Bona, E | 1 |
| Grazzini, I | 1 |
| Gao, P | 1 |
| Guan, L | 1 |
| Zheng, J | 1 |
| Meyskens, FL | 1 |
| McLaren, CE | 1 |
| Gravitz, L | 1 |
| Abedinpour, P | 1 |
| Baron, VT | 1 |
| Welsh, J | 1 |
| Borgström, P | 1 |
| Wang, JL | 1 |
| Lin, KL | 1 |
| Chou, CT | 1 |
| Kuo, CC | 1 |
| Cheng, JS | 1 |
| Hsu, SS | 1 |
| Chang, HT | 1 |
| Tsai, JY | 1 |
| Liao, WC | 1 |
| Chen, IS | 1 |
| Liu, SI | 1 |
| Jan, CR | 1 |
| Armstrong, AJ | 1 |
| Jovic, G | 1 |
| Ritchie, AW | 1 |
| Bertelli, G | 1 |
| Birtle, AJ | 1 |
| Sheehan, D | 1 |
| Srihari, N | 1 |
| Cheung, AS | 1 |
| Grossmann, M | 1 |
| Lam, ET | 1 |
| Flaig, TW | 1 |
| Benson, P | 1 |
| Yudd, M | 1 |
| Sims, D | 1 |
| Chang, V | 1 |
| Srinivas, S | 1 |
| Kasimis, B | 2 |
| Lasalvia-Prisco, E | 1 |
| Goldschmidt, P | 1 |
| Galmarini, F | 1 |
| Cucchi, S | 1 |
| Vázquez, J | 1 |
| Aghazarian, M | 1 |
| Lasalvia-Galante, E | 1 |
| Golomar, W | 1 |
| Gordon, W | 1 |
| Marschner, N | 1 |
| Zaiss, M | 1 |
| Katkoori, VR | 1 |
| Manne, K | 1 |
| Vital-Reyes, VS | 1 |
| Rodríguez-Burford, C | 1 |
| Shanmugam, C | 1 |
| Sthanam, M | 1 |
| Manne, U | 1 |
| Chatla, C | 1 |
| Abdulkadir, SA | 1 |
| Grizzle, WE | 1 |
| Zhu, J | 2 |
| Song, X | 4 |
| Lin, HP | 2 |
| Young, DC | 1 |
| Yan, S | 1 |
| Marquez, VE | 1 |
| Chen, CS | 5 |
| Pan, Y | 1 |
| Zhang, JS | 1 |
| Gazi, MH | 1 |
| Young, CY | 1 |
| Condon, MS | 2 |
| Pruthi, RS | 2 |
| Derksen, JE | 2 |
| Moore, D | 2 |
| Kulp, SK | 3 |
| Yang, YT | 3 |
| Hung, CC | 1 |
| Chen, KF | 1 |
| Lai, JP | 1 |
| Tseng, PH | 3 |
| Fowble, JW | 1 |
| Ward, PJ | 1 |
| Groopman, JD | 1 |
| Piantadosi, SA | 1 |
| Lieberman, R | 1 |
| Feigenberg, SJ | 1 |
| Wolk, KL | 1 |
| Yang, CH | 1 |
| Morris, CG | 1 |
| Zlotecki, RA | 1 |
| Gupta, S | 1 |
| Adhami, VM | 2 |
| Subbarayan, M | 1 |
| MacLennan, GT | 1 |
| Lewin, JS | 1 |
| Hafeli, UO | 1 |
| Fu, P | 1 |
| Mukhtar, H | 2 |
| Huang, JW | 1 |
| Fowble, J | 1 |
| Shiau, CW | 1 |
| Shaw, YJ | 1 |
| Merchan, JR | 1 |
| Jayaram, DR | 1 |
| Supko, JG | 1 |
| He, X | 1 |
| Bubley, GJ | 2 |
| Sukhatme, VP | 1 |
| Zielinski, SL | 1 |
| Pittman, B | 1 |
| Dandekar, DS | 1 |
| Lopez, M | 1 |
| Carey, RI | 1 |
| Lokeshwar, BL | 1 |
| Patel, MI | 1 |
| Subbaramaiah, K | 1 |
| Du, B | 1 |
| Chang, M | 1 |
| Yang, P | 1 |
| Newman, RA | 1 |
| Cordon-Cardo, C | 1 |
| Thaler, HT | 1 |
| Sonpavde, G | 1 |
| Hayes, TG | 1 |
| Pttman, B | 1 |
| Carson, CC | 1 |
| Grigson, G | 1 |
| Watkins, C | 1 |
| Wallen, E | 1 |
| Bosland, M | 1 |
| Becker, G | 1 |
| Bamberg, M | 1 |
| DuBois, RN | 1 |
| Smith, MR | 1 |
| Manola, J | 1 |
| Kaufman, DS | 1 |
| Oh, WK | 1 |
| Kantoff, PW | 1 |
| Nishimura, K | 1 |
| Takayama, H | 1 |
| Nakayama, M | 1 |
| Nonomura, N | 1 |
| Okuyama, A | 1 |
| Ohneseit, PA | 1 |
| Krebiehl, G | 1 |
| Dittmann, K | 1 |
| Kehlbach, R | 1 |
| Rodemann, HP | 1 |
| Malik, A | 1 |
| Zaman, N | 1 |
| Sarfaraz, S | 1 |
| Siddiqui, IA | 1 |
| Syed, DN | 1 |
| Afaq, F | 1 |
| Pasha, FS | 1 |
| Saleem, M | 1 |
| Anai, S | 1 |
| Tanaka, M | 1 |
| Shiverick, KT | 1 |
| Kim, W | 1 |
| Takada, S | 1 |
| Boehlein, S | 1 |
| Goodison, S | 1 |
| Mizokami, A | 2 |
| Rosser, CJ | 1 |
| Madan, RA | 1 |
| Xia, Q | 1 |
| Chang, VT | 1 |
| Oriscello, RG | 1 |
| Albouy, B | 1 |
| Tourani, JM | 1 |
| Allain, P | 1 |
| Rolland, F | 1 |
| Staerman, F | 1 |
| Eschwege, P | 1 |
| Pfister, C | 1 |
| Avila, GE | 1 |
| Patel, J | 1 |
| Kong, AN | 1 |
| Paulino, R | 1 |
| Rabson, AB | 1 |
| Randolph, C | 1 |
| Carles, J | 1 |
| Font, A | 1 |
| Mellado, B | 1 |
| Domenech, M | 1 |
| Gallardo, E | 1 |
| González-Larriba, JL | 1 |
| Catalan, G | 1 |
| Alfaro, J | 1 |
| Gonzalez Del Alba, A | 1 |
| Nogué, M | 1 |
| Lianes, P | 1 |
| Tello, JM | 1 |
| Mehar, A | 1 |
| Takahashi, Y | 1 |
| Kass, GE | 1 |
| Hsu, AL | 1 |
| Ching, TT | 1 |
| Wang, DS | 1 |
| Rangnekar, VM | 1 |
| Johnson, AJ | 2 |
| Hsu, A | 1 |
| Chen, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| A Randomized, Placebo-Controlled Trial Of Celecoxib In Men Pre-Prostatectomy For Clinically Localized Adenocarcinoma Of The Prostate: Evaluation Of Drug-Specific Biomarker Modulation[NCT00022399] | Phase 2 | 73 participants (Actual) | Interventional | 2002-04-25 | Completed | ||
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
2 reviews available for celecoxib and Cancer of Prostate
| Article | Year |
|---|---|
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Anti | 2019 |
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; | 2016 |
17 trials available for celecoxib and Cancer of Prostate
| Article | Year |
|---|---|
Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.
Topics: Aged; Aged, 80 and over; Apoptosis; Celecoxib; Chemoprevention; Cyclooxygenase 2 Inhibitors; Double- | 2017 |
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cele | 2017 |
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphospho | 2009 |
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; | 2009 |
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Ce | 2009 |
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Topics: Aged; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Male; Mi | 2009 |
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Celecoxib; Gonadotropin-Releasing Hormone; Humans | 2012 |
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Celecoxib; Gonadotropin-Releasing Hormone; Humans | 2012 |
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Celecoxib; Gonadotropin-Releasing Hormone; Humans | 2012 |
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Celecoxib; Gonadotropin-Releasing Hormone; Humans | 2012 |
Renal effects of high-dose celecoxib in elderly men with stage D2 prostate carcinoma.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Glomerular Fil | 2012 |
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Carci | 2012 |
A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Topics: Antineoplastic Agents; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2004 |
Celecoxib to decrease urinary retention associated with prostate brachytherapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brachytherapy; Celecoxib; Foreign- | 2003 |
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2005 |
Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Prog | 2006 |
Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.
Topics: Aged; Celecoxib; Combined Modality Therapy; Cyclooxygenase Inhibitors; Humans; Male; Middle Aged; Ne | 2006 |
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Topics: Aged; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase 2 Inhibitors; Humans; Male; Middle Aged; Neo | 2006 |
Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Docetaxel; Human | 2007 |
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Dis | 2007 |
71 other studies available for celecoxib and Cancer of Prostate
| Article | Year |
|---|---|
New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Cell Proli | 2004 |
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carbolines; Cell Line, Tumor; Cell Proliferation; Cyclooxyg | 2010 |
Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2013 |
Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; Humans; Male; Mice; Mice, Inbred C57BL | 2023 |
Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Topics: Adult; Aged; alpha-Tocopherol; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Colonic Neoplasms | 2019 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Topics: Animals; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; HEK2 | 2017 |
The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Topics: Amphiregulin; Androgen Antagonists; Antineoplastic Agents; Apoptosis; Celecoxib; Dose-Response Relat | 2017 |
Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice.
Topics: Adenocarcinoma; Animals; Celecoxib; Cyclooxygenase 2; Disease Models, Animal; Estrogen Receptor alph | 2018 |
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Ce | 2018 |
Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Progre | 2019 |
Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation.
Topics: Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase | 2019 |
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
Topics: Animals; Carcinogenesis; Celecoxib; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygenas | 2019 |
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.
Topics: Adenocarcinoma; Administration, Metronomic; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antine | 2013 |
Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Topics: Animals; Bone Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progressi | 2014 |
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Down-Regulation; Gene Expression | 2014 |
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celeco | 2014 |
EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Prot | 2014 |
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorva | 2014 |
A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.
Topics: Animals; Celecoxib; Diet Therapy; Diet, Carbohydrate-Restricted; Dietary Proteins; Disease Models, A | 2014 |
LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2.
Topics: Benzimidazoles; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cy | 2014 |
An Atomic Force Microscope Study Revealed Two Mechanisms in the Effect of Anticancer Drugs on Rate-Dependent Young's Modulus of Human Prostate Cancer Cells.
Topics: Amino Acids; Celecoxib; Cell Line, Tumor; Cytoskeleton; Disulfiram; Elastic Modulus; Fluorescent Ant | 2015 |
Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Celecoxib; Cycl | 2016 |
Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Topics: CD8-Positive T-Lymphocytes; Celecoxib; Cellular Reprogramming; Cellular Reprogramming Techniques; Ch | 2016 |
Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
Topics: Aging; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Celecoxib; Chemoprevention; Drug Mo | 2017 |
Bone-Targeted Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion, and Controversy.
Topics: Celecoxib; Diphosphonates; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2017 |
[Effects of a selective cyclooxygenase 2 inhibitor celecoxib on the proliferation and apoptosis of human prostate cancer cell line PC-3].
Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenas | 2008 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cell Division; Inflammation; | 2009 |
Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase Inhibitors; Humans; Male; Prostatic Neoplasms | 2009 |
Informative clinical investigation: a demanding taskmaster.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Male; Prostaglandins; Prostatic Ne | 2009 |
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antine | 2010 |
Inflammatory pathogenesis of prostate cancer and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Celecoxib; Chemotherapy, Adjuvant; Cycloox | 2010 |
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineo | 2010 |
Role of leukotriene B4 in celecoxib-mediated anticancer effect.
Topics: Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neopl | 2010 |
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?
Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; | 2010 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase I | 2011 |
Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.
Topics: Androgen Antagonists; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Celecoxib; | 2011 |
Effect of celecoxib on Ca(2+) handling and viability in human prostate cancer cells (PC3).
Topics: Calcium; Calcium Channels, L-Type; Celecoxib; Cell Death; Cell Line, Tumor; Cell Survival; Cyclooxyg | 2012 |
The STAMPEDE trial and celecoxib: how to adapt?
Topics: Androgen Antagonists; Antineoplastic Agents; Celecoxib; Humans; Male; Prostatic Neoplasms; Pyrazoles | 2012 |
COX-2 inhibitors in prostate cancer treatment--hold your horses?
Topics: Antineoplastic Agents, Hormonal; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Drug | 2012 |
Prostate cancer: celecoxib trampled in the STAMPEDE trial.
Topics: Androgen Antagonists; Celecoxib; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Py | 2012 |
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Celecoxib; Dexamethasone | 2012 |
Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53.
Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; | 2013 |
Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Cele | 2002 |
The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells.
Topics: Androgen Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blott | 2003 |
Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bromodeoxyuridine; | 2003 |
3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Apoptosis; Celecoxib; Cell Division; Cell Line, Tumor; | 2004 |
The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Doub | 2002 |
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Celecoxib; Cell Division; Cyclo | 2004 |
From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxyge | 2004 |
Despite positive studies, popularity of chemoprevention drugs increasing slowly.
Topics: Adenomatous Polyposis Coli; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarci | 2004 |
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Cele | 2004 |
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; | 2005 |
A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
Topics: Celecoxib; Cell Proliferation; Chemoprevention; Cyclooxygenase Inhibitors; Docosahexaenoic Acids; Dr | 2005 |
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenas | 2005 |
PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases.
Topics: Adenocarcinoma; Bone Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Humans; Male; Middle Aged; Pro | 2005 |
Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Celecoxib; Cell Growth Processes; Cyclooxygen | 2006 |
Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells.
Topics: Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Docosahexaenoic Acids; Down-Regulation; Electrophor | 2006 |
Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bort | 2006 |
Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; D | 2007 |
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Beverages; Blotting, Western; Celecoxib; Cell Line, Tum | 2007 |
Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Blotting, Western; Cardiovascular Diseases; Celecoxib; Cell Line, Tumor; Cell Surviv | 2007 |
A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Case-Control Studie | 2007 |
Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Topics: Animals; Apoptosis; Atorvastatin; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Drug The | 2007 |
Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclin | 2007 |
The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.
Topics: Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cytotoxins; Gene Expression Regulation, Neoplastic; H | 2008 |
The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2000 |
Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells.
Topics: Apoptosis; Calcium; Celecoxib; Cell Cycle; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2001 |
Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 I | 2002 |